Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02069366 · ClinicalTrials.gov registry record · NA
Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder
A NA study, sponsored by Wayne State University.
- Completed
- Registry status
- NA
- Development phase
- 86
- Enrollment target
NCT02069366 is a NA study that has completed, run by Wayne State University. The registered enrollment target is 86 participants.
The verdict
NCT02069366, a NA study, has completed, sponsored by Wayne State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 86 participants
- Enrollment target
Study Summary
The goal of this study is to look at how a type of drug called cannabinoids are related to the processing of fear signals, the experience of emotions and fear, and the pattern of activity in the brain that is involved in these processes and how this relates to the development of post-traumatic stress disorder (PTSD). PTSD is an anxiety disorder that occurs after experiencing a traumatic event(s) and is characterized by unwanted memories of the trauma(s) through flashbacks or nightmares, avoidance of situations that remind the person of the event, difficulty experiencing emotions, loss of interest in activities the person used to enjoy, and increased arousal, such as difficulty falling asleep or staying asleep, anger and hypervigilance. The information gained from this study could lead to the development of new treatments for persons who suffer from anxiety or fear-based disorders.
Interventions
- DRUG Placebo
- DRUG Dronabinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2014-11 |
| Est. Completion | 2019-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02069366
The ClinicalTrials.gov registry entry for NCT02069366 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wayne State University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02069366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02069366 about?
NCT02069366 is a clinical study titled "Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder". The goal of this study is to look at how a type of drug called cannabinoids are related to the processing of fear signals, the experience of emotions and fear, and the pattern of activity in the brain that is involved in these processes and how this relates to the development of post-traumatic stres...
What is the current status of trial NCT02069366?
This trial is currently completed. It is a NA study. The enrollment target is 86 participants. The study started on 2014-11. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02069366?
The interventions under investigation include: Placebo (DRUG), Dronabinol (DRUG).
Who is sponsoring clinical trial NCT02069366?
This trial is sponsored by Wayne State University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.